MARKETS / BALCAO / BPTH
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Bio-Path Holdings, Inc. BPTH

15 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
EPS · FY24
$-4.12
Dividend / sh · FY24
Payout · FY24
ROE · FY24
-3325.7%
Net margin · FY24
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
Revenue, FY2024 · full 15-year series below
Revenue Net income
1e-052e-053e-054e-05-0.0201020132016201920222024
1e-052e-053e-054e-05-0.02015201820212024

Per share
USD -4.12
Diluted EPS, FY2024
EPS
0.40.81.2-4.12201020132016201920222024
0.40.81.2-4.122015201820212024

The company pays no cash dividend.

Profitability
-3325.7%
Return on equity, FY2024
ROE
0.250.50.751-3325.7%201020132016201920222024
0.250.50.751-3325.7%2015201820212024
Operating margin
Net margin
Return on assets-278.6%

Each USD of equity lost 3326 cents this year.

Returned to shareholders
returned in FY2024 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.01B
Shares outstanding, FY2024
0.050.01201020132016201920222024
0.090.012015201820212024
Change, 5 years+81.7%
Change, 10 years

The share count grew 82% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 3.9M
total assets, end of FY2024
Total assetsUSD 3.9M
EquityUSD 154,000.00
CashUSD 1.2M
Current ratio1.15×

Equity funds 4% of total assets.

History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−4.12
−33.63
−38.12
−1.55
−2.83
−3.24
−14.38
−15.99
−0.73
−0.06
−0.05
−0.05
−0.04
−0.04
−0.04
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−3325.7
−220.0
−70.0
−51.5
−60.2
−77.1
−184.9
−86.1
−74.8
−44.2
−45.9
−96.1
−104.8
−81.8
−72.7
Shares out B
0.01
0.00
0.00
0.01
0.00
0.00
0.00
0.00
0.00
0.09
0.09
0.08
0.06
0.06
0.05

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
44 of 44
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed